The Global Health Body Sounds Alert Over Critical Lack of Obesity Injections

Fewer than 10% of patients that would benefit from obesity jabs such as Wegovy are able to get them, states the World Health Organization as it releases its initial recommendations on the therapies.

With over a billion individuals worldwide currently obese, it is advocating for increased and just availability to these injectable treatments.

Based on projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.

"Our latest guidelines acknowledges that obesity is a lifelong illness that can be managed with holistic and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to universal access to the jabs that can aid individuals in losing substantial body mass, notes the body.

Weight-Loss Drug Supply Crisis

Even in the present most favorable case, the production of GLP-1 therapies could only cover around 100 million people – under 10% of eligible patients, per the WHO.

The guideline urges countries and companies to expand availability, by approaches like voluntary licensing.

A patent on a key compound – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.

The Way Obesity Injections Function

GLP-1 drugs replicate a natural hormone to reduce digestion speed, curb appetite and boost satiety so people eat less.

Individuals typically see weight reduction in the initial weeks of starting on the weekly injections.

Studies points to users may see weight return within a year of halting the drug, because their typical food cravings return.

Being above a healthy weight increases your chance for experiencing diseases, such as diabetes, heart disease, stroke, and certain cancers.

Obesity concerns individuals in countries worldwide and was associated with millions of fatalities worldwide in 2024, per the WHO.